JPRN-UMIN000009845已完成未知
A phase II trial of S-1 monotherapy for relapsed thymoma and thymic carcinoma: Okayama Lung Cancer Study Group Trial (OLCSG 1302) - S-1 monotherapy for relapsed thymoma and thymic carcinoma.
Okayama Lung Cancer Study Group(OLCSG)0 个研究点目标入组 30 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Serious uncontrolled infections or body temperature higher than 38 degree centigrade 2. Continuous administration of an oral steroid or an immunosuppressive agent 3. With severe concurrent disease 4. Symptomatic brain metastasis 5. With malignant pleural, peritoneal effusion requiring drainage or pericardial effusion 6. With severe drug allergies 7. Contraindication with S-1 8. Previous treatment with fluoropyrimidines such as S-1, UFT 9. Current use of flucytosine 10. With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray 11. Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 12. Physician concludes that the patient's participation in this trial is inappropriate
研究者
相似试验
已完成
不适用
Phase II study of S-1 for relapsed or refractory thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000008174orth Japan Lung Cancer Group40
未知
2 期
Randomized phase II trial of TS-1 monotherapy versus TS-1 plus gemcitabine therapy in patients with gemcitabine-resistant advanced pancreatic cancerPatients with unresectable advanced pancreatic cancer (Stage IV, TNM Classification) who were primarily resistant to gemcitabine monotherapyJPRN-UMIN000001103Keio University School of Medicine, Department of Medicine, Division of Gastroenterology80
已完成
2 期
Multicenter phase II study of oral S-1 monotherapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapiesColorectal cancerJPRN-UMIN000006487Chube Clinical Oncology Group (CCOG)34
招募中
2 期
Phase II study of S-1 monotherapy as 1st line chemotherapy in patients > or = 80 with advanced non-small cell lung cancerpatients >or = 80 with advanced non-small cell lung cancerJPRN-UMIN000008490Shinshu University Hospital35
已完成
不适用
Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatmentsesophageal cancerJPRN-UMIN000023736Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine50